Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2020

In 2020, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 10.10% of shares outstanding on 15 Jan 2020 to 20.91% on 31 Dec 2020, a change of +10.81 percentage points. The year's high was 23.41% on 13 Nov 2020 and its low 5.31% on 31 Mar 2020, averaging 13.29% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.49 days on 31 Dec 2020. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2020

2020 in figures

Start of year
10.10% (15 Jan 2020)
End of year
20.91% (31 Dec 2020)
Change
+10.81 pp
High
23.41% (13 Nov 2020)
Low
5.31% (31 Mar 2020)
Average
13.29%
Highest days to cover
4.49 (31 Dec 2020)
SEC filings marked
8

Every report in 2020

FILANA THERAPEUTICS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202010.10%1.00
31 Jan 20208.19%1.00
14 Feb 20208.35%1.00
28 Feb 20206.91%1.07
13 Mar 20206.38%1.45
31 Mar 20205.31%1.8810-K filed, results (8-K)
15 Apr 20207.07%2.98
30 Apr 20209.61%2.01
15 May 202010.02%1.8910-Q filed, results (8-K)
29 May 202012.01%1.00
15 Jun 202011.50%1.00
30 Jun 202013.70%1.57
15 Jul 202014.15%1.37
31 Jul 202012.56%2.93
14 Aug 202011.59%1.2810-Q filed, results (8-K)
31 Aug 202012.11%3.98
15 Sep 202011.17%1.00
30 Sep 202019.98%1.00
15 Oct 202018.63%2.92
30 Oct 202021.50%2.58
13 Nov 202023.41%1.0010-Q filed, results (8-K)
30 Nov 202023.35%2.15
15 Dec 202020.34%4.25
31 Dec 202020.91%4.49

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.